Proficio Capital Partners LLC Makes New Investment in Ascendis Pharma A/S (NASDAQ:ASND)

Proficio Capital Partners LLC acquired a new stake in Ascendis Pharma A/S (NASDAQ:ASND) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 12,528 shares of the biotechnology company’s stock, valued at approximately $1,725,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Groupama Asset Managment acquired a new stake in shares of Ascendis Pharma A/S during the third quarter worth about $60,000. Janus Henderson Group PLC raised its stake in shares of Ascendis Pharma A/S by 6.8% in the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after acquiring an additional 267,881 shares in the last quarter. Westfield Capital Management Co. LP raised its holdings in Ascendis Pharma A/S by 3.4% in the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock valued at $766,523,000 after acquiring an additional 170,942 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Ascendis Pharma A/S by 9.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock worth $278,760,000 after purchasing an additional 155,971 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. purchased a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at about $19,908,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on ASND shares. StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Cantor Fitzgerald upped their target price on Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, February 25th. Evercore ISI lifted their price target on Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 18th. The Goldman Sachs Group boosted their price objective on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. Finally, JPMorgan Chase & Co. raised their target price on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an “overweight” rating in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $204.64.

Ascendis Pharma A/S Stock Performance

ASND opened at $166.05 on Thursday. The company has a market cap of $10.08 billion, a price-to-earnings ratio of -23.39 and a beta of 0.62. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $169.37. The business’s fifty day moving average is $140.06 and its two-hundred day moving average is $135.30.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.64. On average, analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.